{
  "source": "PA-Med-Nec-Tavneos.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2265-4\nProgram Prior Authorization/Medical Necessity\nMedication Tavneos® (avacopan)\nP&T Approval Date 1/2022, 1/2023, 1/2024, 1/2025\nEffective Date 4/1/2025\n1. Background:\nTavneos (avacopan) is a complement 5a receptor (C5aR) antagonist indicated as an\nadjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic\nautoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and\nmicroscopic polyangiitis [MPA]) in combination with standard therapy including\nglucocorticoids. Tavneos does not eliminate glucocorticoid use.\n2. Coverage Criteria a:\nA. Anti-Neutrophil Cytoplasmic Autoantibody (ANCA) - Associated Vasculitis\n1. Initial Authorization\na. Tavneos will be approved based on all of the following criteria:\n(1) Diagnosis of severe active ANCA-associated vasculitis\n-AND-\n(2) Submission of medical records (e.g., chart notes, laboratory values, etc.)\ndocumenting the disease is one of the following types:\n(a) Granulomatosis with polyangiitis (GPA)\n(b) Microscopic polyangiitis (MPA)\n-AND-\n(3) Patient is being treated with an initial immunosuppressive regimen to induce\nremission (i.e., rituximab, cyclophosphamide)\n-AND-\n(4) Tavneos is being prescribed as adjunctive treatment in combination with standard\ntherapy (e.g. prednisone, azathioprine, mycophenolate, methotrexate, rituximab,\ncyclophosphamide)\n-AND-\n(5) Prescribed by one of the following:\n© 2025 UnitedHealthcare Services, Inc.\n1\n(a) Rheumatologist\n(b) Nephrologist\n(c) Pulmonologist\n(d) Vascular Medicine Specialist\nAuthorization will be issued for 6 months.\n2. Reauthorization\na. Tavneos will be approved based on all of the following criteria:\n(1) Patient does not show evidence of progressive disease while on Tavneos therapy\n-AND-\n(2) Tavneos is being prescribed as adjunctive treatment in combination with standard\ntherapy (e.g. prednisone, azathioprine, mycophenolate, methotrexate, rituximab,\ncyclophos",
    " on Tavneos therapy\n-AND-\n(2) Tavneos is being prescribed as adjunctive treatment in combination with standard\ntherapy (e.g. prednisone, azathioprine, mycophenolate, methotrexate, rituximab,\ncyclophosphamide)\n-AND-\n(3) Prescribed by or in consultation with one of the following:\n(a) Rheumatologist\n(b) Nephrologist\n(c) Pulmonologist\n(d) Vascular Medicine Specialist\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-\n10) and/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits may be in place.\n© 2025 UnitedHealthcare Services, Inc.\n2\n4. References:\n1. Tavneos [package insert]. Cincinnati, OH: Thermo Fisher Scientific; June 2024.\nProgram Prior Authorization/Medical Necessity - Tavneos® (avacopan)\nChange Control\n1/2022 New program\n1/2023 Annual review with no change to coverage criteria.\n1/2024 Annual review with no changes.\n1/2025 Annual review with no changes to coverage criteria. Updated reference.\n© 2025 UnitedHealthcare Services, Inc.\n3"
  ]
}